SUMMARY Sub-Sahara Africa with just 10% of the world’s population bears a disproportionate 68% of the global burden of the Human Immunodeficiency Virus/ Acquired Immune Deficiency Syndrome (HIV/AIDS) with children, women and young adults at greater risk. Ocular findings are a significant cause of morbidity and differ in different environments. With availability of Highly Active Antiretroviral Therapy (HAART), and improvement in life expectancy, the Ophthalmologists needs to be prepared to receive more cases of ocular involvements in HIV/AIDS. This study investigates ocular findings among patients attending the Special Treatment Clinic of the University of Calabar Teaching Hospital, Calabar, Cross River State. Using a descriptive cross sectional study design HIV/AIDS patients aged above 16 were recruited into the study after an informed consent was obtained, by a systematic sampling technique. Eye examination findings at enrollment were documented. The group of patients on HAART for ≤ 6 months was compared with subjects who have been on HAART for > 6months. All statistical data analysis was performed using STATA version 10. A total of 440 subjects met the inclusion criteria and were recruited into the study. The modal age-group was 26 to 35 and formed 40.4% of study population while 94.3% of the study population was 55years and less. This study shows a female preponderance with a male to female ratio of 1:1.6. 74.5% of the study population was gainfully employed. Traders formed the largest group 125 (28.4%) while the smallest group, 21 (4.8%) of the study population were students. Only 155 (35.2%) of the study population had ocular symptoms while the majority of respondents were asymptomatic. Visual impairment 154 (35.0%) led the group and eye growth 15 (3.4%) was the least common symptom. There was no case of bilateral blindness. However 1.4% of the study population was blind in the right eye, 0.9% on the left eye. There was a very strong relationship between CD4+ count and ocular involvement with increased ocular involvement for lower CD4+ counts (p<0.0001). While 316 (72%) of respondents had some ophthalmic morbidity not necessarily HIV/AIDS related, 136 (30.91%) of respondents had specific HIV/AIDS related ophthalmic morbidity. Common among them, retinal microangiopathy affecting 60 (13.6%) of respondents. Conjunctival microvasculopathy affected a total of 30 (6.8%) respondents. Hypertricosis was seen in 22 (5%), dry eye syndrome in 17 (3.9%), anterior uveitis in 17 (3.9%), presumed squamous cell carcinoma of the conjunctiva affected 7 (1.6%) and Kaposi sarcoma was seen in 4 (0.91%) respondents 1 of whom had bilateral disease. Facial nerve palsy affected 5 (1.14%) respondents. There was significant reduction in the prevalence of trichomegaly in the > 6 months HAART group compared to the ≤ 6 months HAART group. p= 0.0219. Being on HAART for >6 months appeared to make respondents less symptomatic, p= <0.001. Introduction of ophthalmic care into special treatment programmes, and routine referral of patients to Ophthalmologists for examination at diagnosis and CD4+ of 350 cells and below have been recommended.